Preferred Stock Channel
Market News Video Self Directed Investor The Warren Buffetts Next Door Stock message boards
Quotes delayed 20 minutes


Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
www.valueforum.com/7/
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Wednesday, April 24, 8:20 AM

Slide #395. Ventrus Biosciences, Inc. Preferred Stock Offering

Company: Ventrus Biosciences, Inc. (NASDAQ:VTUS)
Date announced: 1/29/2013
Shares Offered: 220,000
Date of Pricing: 1/30/2013
Price Per Share: $25.00
Closed Date: 2/4/2013
Preferred Stock Offering Details: Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced today that it is concurrently offering to sell, subject to market and other conditions, (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series A Convertible Preferred Stock ("Series A") in a separate underwritten public offering. The Series A is non-voting and each share of Series A is convertible into 10 shares of Ventrus common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of Ventrus shares of common stock then outstanding. All of the shares in these offerings are to be sold by Ventrus. Ventrus also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the common stock public offering to cover over-allotments, if any.

Ventrus Biosciences is a development stage pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically anal disorders. Co.'s product candidate portfolio consists of two in-licensed late-stage drugs: VEN 307 (topical diltiazem), which is intended to treat pain associated with anal fissures; and VEN 308 (topical phenylephrine), which is intended to treat fecal incontinence. These candidates are two molecules that were previously approved and as of Dec 31 2012, were marketed for other indications and that have been formulated into Co.'s topical treatments for these new gastrointestinal indications.
Open the VTUS Page at Preferred Stock Channel »

Name:  Assembly Biosciences Inc
Website:  www.ventrusbio.com
Sector:  Drugs & Pharmaceuticals
 

Open the VTUS Page at Preferred Stock Channel (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 395 of 457 | www.PreferredStockChannel.com | Copyright © 2011 - 2019, All Rights Reserved

Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.